Background
Osteoporosis and age-related bone loss represent major clinical consequences of the GH/IGF-1 decline accompanying the somatopause. GH and IGF-1 are primary anabolic signals for bone formation — GH stimulates osteoblast proliferation and differentiation while IGF-1 promotes collagen synthesis and bone mineralization. Age-related decline in GH pulsatility correlates directly with decreasing bone mineral density and increased fracture risk in elderly populations.
MK-677 (ibutamoren) is an orally active, non-peptide GH secretagogue that stimulates GH release via the ghrelin receptor (GHSR-1a), raising circulating IGF-1 in a sustained, dose-dependent manner. Murphy and colleagues evaluated whether 12 months of oral MK-677 could activate bone remodeling markers in a cohort spanning young and elderly adults — providing a clinical assessment of the bone-anabolic potential of GH secretagogue class compounds.
Methods
Design: Randomized, double-blind, placebo-controlled parallel-group trial
Population: 65 adults stratified into:
- Young adults (18–40 years, n=32): MK-677 25 mg/day vs placebo
- Elderly adults (60–81 years, n=33): MK-677 25 mg/day vs placebo
Duration: 12 months
Primary outcomes: Serum IGF-1, bone formation markers (osteocalcin, PICP — procollagen type I C-terminal propeptide), bone resorption marker (ICTP — type I collagen C-terminal telopeptide)
Secondary: Body composition (DEXA), fasting glucose, insulin
Key Findings
GH Axis Activation:
- IGF-1 increased 40–50% from baseline (both age groups) vs. minimal change in placebo
- Elevation sustained across the 12-month treatment period without tachyphylaxis
- IGF-1 levels in elderly subjects approached younger adult reference ranges
Bone Turnover Markers:
| Marker | Type | MK-677 Change | Placebo Change | p-value |
|---|---|---|---|---|
| Osteocalcin | Formation | +20% | −2% | < 0.05 |
| PICP | Formation | +26% | +1% | < 0.05 |
| ICTP | Resorption | +22% | +2% | < 0.05 |
- Coupled increase in both bone formation and resorption markers indicates activation of bone remodeling, not isolated resorption (osteoclast only), which would be adverse
- Formation/resorption coupling ratio maintained — consistent with net anabolic bone effect
- Effects observed in both young and elderly groups, suggesting preserved pituitary-bone axis responsiveness
Body Composition:
| Parameter | MK-677 | Placebo | Change |
|---|---|---|---|
| Fat-free mass (elderly) | +1.4 kg | −0.3 kg | +1.7 kg* |
| Fat mass (elderly) | −0.9 kg | +0.5 kg | −1.4 kg* |
*Consistent with GH-mediated body composition shifts established in prior acute studies
Metabolic Safety:
- Fasting glucose: slight increase (mean +0.4 mmol/L) in elderly MK-677 group — statistically significant but within normal glycemic range
- Fasting insulin: increased ~20% — consistent with GH-induced mild insulin resistance
- No new-onset diabetes observed
- Increased appetite reported in 62% of MK-677 subjects (ghrelin receptor activation effect)
Bone Remodeling Mechanism
GH/IGF-1 activation of bone involves a well-characterized cascade:
- Osteoblast activation: GH directly stimulates osteoblast proliferation via JAK2/STAT5; IGF-1 promotes type I collagen synthesis (reflected by PICP)
- Coupled resorption: Bone remodeling is a coupled process — osteoblast activation recruits osteoclasts through RANKL/OPG signaling; ICTP rise reflects this coupling, not uncoupled bone destruction
- Long-term net effect: In growth hormone-deficient states (as in aging), restoration of GH axis reverses the low-turnover state of senescent bone — even coupled increases in turnover markers produce net bone gains over time as formation outpaces resorption
Clinical Significance
- Bone anabolic potential: MK-677 activates coupled bone remodeling — the same mechanism by which anabolic therapies like teriparatide produce bone formation — through physiological GH axis restoration
- Fracture risk implications: The low-turnover, atrophic bone state of GH-deficient elderly adults is associated with fragility fractures; secretagogue-driven remodeling activation may shift this trajectory
- 12-month durability: Unlike acute GH studies that normalize within weeks, the 12-month sustained IGF-1 elevation and bone marker changes suggest durable anabolic signaling without axis desensitization
- Tolerability in elderly: The favorable profile supports the potential for long-term administration, though glucose monitoring is warranted given the modest fasting glucose increase
Limitations
- 12 months may be insufficient to detect changes in bone mineral density (BMD); BMD studies typically require 18–24 months
- Bone turnover markers correlate with BMD changes but are not direct fracture risk measures; fracture endpoint studies are needed
- Glucose elevation warrants caution in pre-diabetic or diabetic populations — the 25 mg daily dose may require dose adjustment or monitoring in higher-risk subjects
- Study population was well-nourished; results may not translate to frail, malnourished elderly with baseline anemia or hypoproteinemia
- No fracture data — the translational step from bone turnover markers to clinical fracture prevention requires longer-term outcomes trials